Shares of BioSyent Inc. (CVE:RX – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as C$16.25 and last traded at C$16.16, with a volume of 1571 shares trading hands. The stock had previously closed at C$15.99.
BioSyent Stock Performance
The company has a debt-to-equity ratio of 6.85, a current ratio of 2.07 and a quick ratio of 6.91. The company’s fifty day simple moving average is C$14.81 and its two-hundred day simple moving average is C$14.74. The stock has a market cap of C$179.46 million, a price-to-earnings ratio of 18.58 and a beta of 1.00.
Insider Activity at BioSyent
In related news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of C$14.65, for a total value of C$27,600.60. Following the sale, the director owned 37,261 shares in the company, valued at C$545,873.65. This represents a 4.81% decrease in their position. Insiders have sold 5,509 shares of company stock worth $82,004 over the last ninety days. Insiders own 33.65% of the company’s stock.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Recommended Stories
- Five stocks we like better than BioSyent
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
